Ignite Creation Date:
2024-05-05 @ 4:36 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00278616
Status:
WITHDRAWN
Last Update Posted:
2012-04-11
First Post:
2006-01-16
Brief Title:
Hematopoietic Stem Cell Transplantation in Patients With Antiphospholipid Syndrome
Sponsor:
Richard Burt MD
Organization:
Northwestern University
Study Overview
Official Title:
High Dose Cyclophosphamide CAMPATH-1H With Hematopoietic Stem Cell Transplantation in Patients With Refractory Antiphospholipid Syndrome APS A Phase I Trial
Status:
WITHDRAWN
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Antiphospholipid syndrome is disease believed to be due to immune cells cells which normally protect the body but are now producing the protein which leads to abnormal clotting in the body This study is designed to examine whether treating patients with high dose cyclophosphamide together with CAMPATH drugs which reduce the function of the immune system followed by return of the previously collected stem cells will result in improvement in the disease Stem cells are undeveloped cells that have the capacity to grow into mature blood cells which normally circulate in the blood stream The purpose of the intense chemotherapy is to destroy the cells in the immune system which may be causing the disease The purpose of the stem cell infusion is to produce a normal immune system that will no longer attack the body The study purpose is to examine whether this treatment will result in improvement in the disease The drugs used in this study treatment are drugs for commonly used for immune suppression
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None